ArticleCureus2026
Clinical Outcomes and Safety of Intralesional Vitamin D3 for Cutaneous Warts: A Retrospective Cohort Study From Sana'a, Yemen.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cutaneous warts are common lesions caused by human papillomavirus (HPV). Conventional destructive therapies are often painful and associated with high recurrence rates. Intralesional vitamin D3 has emerged as an immunotherapeutic option, though clinical evidence remains inconsistent. This study evaluated the clinical outcomes and safety of intralesional vitamin D3 in a cohort of Yemeni patients. Methods This retrospective cohort study evaluated patients treated at two dermatology clinics in Sana'a, Yemen, between January and June 2025. Consecutive patients meeting the inclusion criteria were enrolled. Sixty-one patients with cutaneous warts received intralesional vitamin D3 (60,000-150,000 IU per session) biweekly for up to six sessions. The primary outcome was complete cure, defined as the total disappearance of all treated warts and restoration of normal skin texture. Secondary outcomes included partial response (≥50% reduction), adverse events, and recurrence rates. Data were analyzed using descriptive statistics and univariate logistic regression. Results The median patient age was 18 years (IQR 15-34), and 77.0% (n = 47) were female. Complete cure was observed in 36 patients (59.0%), while 20 (32.8%) showed partial improvement, yielding an overall response rate of 91.8% (95% CI 82.4-96.5). Procedural pain was the most common adverse event (75.4%), followed by transient localized erythema or swelling (13.1%). No serious adverse events or scarring occurred. No recurrence was documented during the six months of follow-up. In univariate analysis, younger age was associated with higher odds of complete response (OR 0.87 per one-year increase, 95% CI 0.81-0.93; p < 0.001). Conclusions Intralesional vitamin D3 was associated with a complete response in approximately 60% of patients and demonstrated a favorable short-term safety profile in this retrospective cohort. However, given the retrospective uncontrolled design, modest sample size, and limited follow-up, randomized controlled trials are required to establish definitive efficacy and control for spontaneous regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.